EverHint – EMA10 × EMA30 Crossover – Top 10 Buy and Top 7 Sell Signals for Mar 31, 2026

Market Context

The broad market rally, with the S&P 500 up 2.92%, Nasdaq advancing 3.83%, and Dow Jones gaining 2.49%, signals a strong bullish trend and heightened risk appetite among investors. This environment favors momentum-based strategies like the EMA10/EMA30 crossover, which thrive in directional moves by capturing short-term trends when the faster EMA crosses above the slower one. Declining volatility, as evidenced by the VIX dropping 17.51% to 25.25, reduces intraday swings and whipsaw risks, allowing these signals to perform more reliably without excessive false positives from choppy price action.

Despite elevated VIX levels indicating lingering caution, the sharp contraction supports a stabilizing backdrop for intraday trading, where EMA signals can align with the prevailing uptrend across major indices. Positive risk sentiment, led by outperformance in growth-oriented areas like the Nasdaq, encourages rotation into sectors showing strength, with Healthcare emerging as the top sector amid 45 total signals. This suggests defensive resilience within a risk-on rally, potentially amplifying EMA buy signals in Healthcare as investors seek balanced exposure.

Sector rotation dynamics further bolster the strategy's efficacy, as broad gains reduce the likelihood of sharp reversals that could invalidate crossovers. In this context, the concentration of signals in Healthcare implies opportunistic momentum plays, benefiting from lower volatility that preserves trend integrity across the session.

👉 And as usual, be careful with EMA-based signals right now. In a market where one POTUS tweet can change direction in minutes, even the cleanest setup can fall apart fast.

What This Signal Is (Quick)

This strategy detects fresh crossovers between the 10-day exponential moving average (EMA10) and the 30-day exponential moving average (EMA30):

• Buy Signal (EMA10_x_EMA30_Buy): EMA(10) crosses above EMA(30) on today's close

  • Short-term momentum overtakes medium-term trend
  • Suggests acceleration in upward price movement
  • Ideal for swing trading (1-4 week holding periods)

• Sell Signal (EMA10_x_EMA30_Sell): EMA(10) crosses below EMA(30) on today's close

  • Short-term momentum weakens below medium-term trend
  • Suggests deceleration or reversal of upward movement
  • Can signal exit points or short entry opportunities

Key Characteristics:

• Uses two EMAs (both exponential) for faster response to price changes
• More responsive than EMA10 x SMA50, generating more frequent signals
• Better suited for capturing short-to-medium term momentum shifts
• Higher sensitivity means more signals but also higher whipsaw risk in choppy markets

Key Criteria:

• Buy: EMA10 crosses above EMA30

• Sell: EMA10 crosses below EMA30

• Minimum ADV: $40M (liquidity filter)

• Earnings buffer: 7 days pre/post earnings

• Fresh crossover: Detected on today's close

Holding Period: 1-4 weeks
Risk Level: Medium

How We Ranked Today

Ranked by RSI (lower RSI for buy signals = more oversold)

📈 Buy-Side Signals (Top 10 of 38 total)

Ranked by RSI (lower RSI for buy signals = more oversold):

📉 Sell-Side Signals (7 Total)

Ranked by RSI (higher RSI for sell signals = more overbought):

Field Notes

Sector concentration: Healthcare (21), Consumer Cyclical (7), Technology (4)

Insider selling: SXI (Standex International Corporation, $-129K), CNX (CNX Resources Corporation, $-1.9M), CYTK (Cytokinetics, Incorporated, $-985K)

Near-term earnings: AEHR (Aehr Test Systems) report within 7 days. Higher volatility risk.

Data coverage: 22.2% insider, 0.0% congressional, 88.9% earnings, 100.0% analyst, 37.8% news

Peer Analysis

Understanding how these stocks relate to their industry peers:

AEHR (Aehr Test Systems): Leads 10 peers: SKYT ($27.41, +4.7%), ICHR ($46.61, +10.7%), IMOS ($35.78, +1.6%), AOSL ($22.16, +6.4%), LAES ($2.62, +13.4%) | Peer of: CEVA ($18.69, +8.6%), ICHR ($46.61, +10.7%), IMOS ($35.78, +1.6%) and 2 more

IOVA (Iovance Biotherapeutics, Inc.): Leads 9 peers: DNA ($6.13, +11.9%), MBX ($29.85, +10.9%), ERAS ($16.18, +8.3%), REPL ($7.65, +6.2%), MGTX ($8.66, +7.0%) | Peer of: ARVN ($10.60, +4.1%), AVBP ($23.07, +9.8%), CTMX ($4.70, +6.6%) and 10 more

MDU (MDU Resources Group, Inc.): Leads 10 peers: SEB ($5654.02, +2.5%), MWA ($27.49, +2.4%), GFF ($72.68, +3.0%), IEP ($7.55), ATMU ($56.77, +3.6%) | Peer of: AGX ($543.87, +5.6%), ATMU ($56.77, +3.6%), FELE ($92.17, +1.8%) and 6 more

TDOC (Teladoc Health, Inc.): Leads 10 peers: SDGR ($11.36, +2.6%), OMDA ($12.57, +4.4%), PHVS ($28.25, +3.5%), PHR ($8.38, -26.6%), PGNY ($16.98, +0.1%) | Peer of: AZTA ($21.13, +4.3%), ESTA ($56.78, +3.8%), EVO ($2.50, +5.9%) and 7 more

CELC (Celcuity Inc.): Leads 10 peers: CGON ($67.68, +5.8%), AAPG ($23.87, +3.1%), CNTA ($39.72, +44.0%), APGE ($84.17, +6.9%), XENE ($58.15, +4.7%) | Peer of: AAPG ($23.87, +3.1%), APGE ($84.17, +6.9%), ARQT ($23.56, +10.4%) and 13 more

TNDM (Tandem Diabetes Care, Inc.): Leads 10 peers: IART ($9.42, +3.3%), KOD ($38.12, +13.2%), NRIX ($15.50, +5.7%), INMD ($13.68, +2.0%), URGN ($17.98, +5.8%) | Peer of: AXGN ($33.13, +5.8%), IART ($9.42, +3.3%), INMD ($13.68, +2.0%) and 2 more

LGND (Ligand Pharmaceuticals Incorporated): Leads 10 peers: PRAX ($322.19, +16.6%), BLTE ($159.44, +6.9%), MIRM ($92.38, +5.1%), ACAD ($22.26, +5.7%), ADMA ($9.01, -1.5%) | Peer of: ACAD ($22.26, +5.7%), ADMA ($9.01, -1.5%), BLTE ($159.44, +6.9%) and 5 more

LQDA (Liquidia Corporation): Leads 9 peers: COGT ($38.50, +8.8%), RCUS ($21.60, +4.6%), IBRX ($7.67, +15.2%), DNLI ($19.20, +6.2%), OCUL ($8.47, +14.5%) | Peer of: AGIO ($33.83, +14.2%), AORT ($36.62, +3.4%), COGT ($38.50, +8.8%) and 7 more

HIMX (Himax Technologies, Inc.): Leads 10 peers: PLAB ($40.41, +9.3%), VECO ($33.86, +3.1%), LASR ($57.02, +5.6%), ADEA ($24.03, +3.9%), MXL ($17.39, +8.2%) | Peer of: BHE ($56.06, +4.7%), CNXN ($58.46, +2.1%), FLYW ($11.64, +1.3%) and 8 more

XPO (XPO Logistics, Inc.): Leads 10 peers: JBHT ($211.90, +3.5%), EXPD ($143.23, +1.2%), CHRW ($166.07, +2.6%), ZTO ($25.17, +3.5%), MTZ ($321.74, +5.2%) | Peer of: CHRW ($166.07, +2.6%), EXPD ($143.23, +1.2%), JBHT ($211.90, +3.5%) and 6 more

EBAY (eBay Inc.): Leads 10 peers: CCL ($25.88, +8.0%), JD ($29.57, +2.2%), TSCO ($45.30, -0.2%), YUM ($155.48, +0.6%), CUK ($25.77, +8.0%) | Peer of: BABA ($125.49, +2.9%), CCL ($25.88, +8.0%), CMG ($31.99, +2.6%) and 12 more

AA (Alcoa Corporation): Leads 10 peers: MOS ($25.50, +2.1%), HMY ($15.39, +8.7%), CDE ($18.77, +13.8%), SUZ ($10.01, +4.2%), WLK ($116.82, +0.7%) | Peer of: CDE ($18.77, +13.8%), HMY ($15.39, +8.7%), ICL ($5.18, -0.2%) and 5 more

CNX (CNX Resources Corporation): Leads 10 peers: CHRD ($142.18, -2.8%), MTDR ($63.18, -2.6%), VIST ($75.47, -1.4%), NE ($49.07, +0.4%), TGS ($34.61, -0.2%) | Peer of: CHRD ($142.18, -2.8%), CRK ($21.08, -3.7%), FRO ($34.86, +4.4%) and 13 more

BIIB (Biogen Inc.): Leads 10 peers: INCY ($94.12, +4.2%), LH ($266.81, +1.2%), GMAB ($26.83, +3.9%), UTHR ($592.98, +0.8%), TEVA ($30.12, +6.2%) | Peer of: BNTX ($88.88, +4.3%), DXCM ($62.80, +1.4%), INCY ($94.12, +4.2%) and 5 more

AAP (Advance Auto Parts, Inc.): Leads 10 peers: ASO ($56.45, +4.0%), RH ($139.91, +5.8%), VSCO ($46.36, +7.1%), BKE ($50.36, +2.0%), AEO ($16.70, +3.8%) | Peer of: AEO ($16.70, +3.8%), ASO ($56.45, +4.0%), BKE ($50.36, +2.0%) and 3 more

SXI (Standex International Corporation): Leads 10 peers: AMSC ($33.85, +5.1%), KAI ($292.35, +2.6%), ATS ($28.20, +4.0%), EPAC ($36.47, +3.6%), HLIO ($64.71, +3.1%) | Peer of: AIR ($109.46, +6.1%), AMSC ($33.85, +5.1%), ATS ($28.20, +4.0%) and 8 more

SLS (SELLAS Life Sciences Group, Inc.): Leads 9 peers: NTHI ($7.01, +0.1%), MDWD ($16.11, +4.2%), TARA ($5.21, +7.4%), IVVD ($1.30, +9.2%), CDXS ($1.63, +7.2%) | Peer of: ARMP ($9.81, +14.3%), CHRS ($1.69, +5.6%), EPRX ($7.24, +9.5%) and 4 more

Recent Headlines

AA (Alcoa Corporation)

• Percheron flags ASCO nod for HMBD-002 cancer therapy data (source)
• Traders Purchase Large Volume of Call Options on Alcoa (NYSE:AA) (source)
• Underappreciated Aluminum Stock Surges With Metal Prices (source)
• Alcoa leads aluminium rally after Iranian strikes hit gulf smelters (source)
• Dow Jones leads markets higher as Trump says Iran talks 'serious' (source)
• Alcoa Stock Was Getting Hit by Iran War. Why It's Now Surging. (source)
• Alcoa leads aluminium rally after Iranian strikes hit gulf smelters (source)
• Alcoa $AA Stake Increased by Pallas Capital Advisors LLC (source)

AAP (Advance Auto Parts, Inc.)

• 2 Auto Retail Parts Stocks Still Worth Tracking in a Slowing Market (source)

AEHR (Aehr Test Systems)

• Why Aehr Test Systems Stock Jumped Today (source)
• Aehr Wins Major New Silicon Photonics Customer with High-Power FOX-XP Wafer-Level Burn-In System for Hyperscale Data Center Optical Interconnect Market (source)
• Semiconductor Stock Flashing Bull Signal Before Earnings (source)
• Aehr Test Systems to Announce Third Quarter Fiscal 2026 Financial Results on April 7, 2026 (source)

BIIB (Biogen Inc.)

• Biogen Stock Pops After FDA Approves New High-Dose Spinraza For Spinal Muscular Atrophy (source)
• Biogen high-dose Spinraza approval seen supporting long-term growth (source)
• Biogen high-dose Spinraza approval seen supporting long-term growth (source)
• US FDA approves higher-dose of Biogen's genetic disorder drug (source)
• FDA Approves New High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy (source)
• Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease Activity (source)
• Generali Investments CEE investicni spolecnost a.s. Purchases 4,797 Shares of Biogen Inc. $BIIB (source)
• Here's Why Biogen Inc. (BIIB) is a Strong Value Stock (source)
• Alteogen Enters into a License Agreement with Biogen for Development and Commercialization of Hybrozyme™-Based Subcutaneous Biologics (source)

CELC (Celcuity Inc.)

• Why Celcuity Stock Popped Today (source)
• Celcuity Inc. (CELC) Q4 2025 Earnings Call Transcript (source)
• Celcuity Inc. Reports Release of Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update (source)

EBAY (eBay Inc.)

• 1 Undervalued Dividend Stock Investors Can Buy Now (source)
• eBay Launches 'The NYC Edit,' Revealing What New York's Most 'In-the-Know' Tastemakers Are Selling and Buying (source)
• Contravisory Investment Management Inc. Has $1.11 Million Holdings in eBay Inc. $EBAY (source)

LGND (Ligand Pharmaceuticals Incorporated)

• CLO Sells LGND 5,000 Shares for $1.0 Million (source)
• Ligand Advances Strategic Growth with Expanded and Strengthened Business Development Team (source)

LQDA (Liquidia Corporation)

• The Chief Commercial Officer of Liquidia (LQDA) Sold 80,000 Shares for $2.8M (source)

MDU (MDU Resources Group, Inc.)

• Montage Gold announces grade control results and resource increase for its Koné and Gbongogo Main deposits at its Koné Project (source)

XPO (XPO Logistics, Inc.)

• Two XPO Leaders Named 2026 Top Women to Watch in Trucking (source)

Carlo's Take (EverHint)

Today's signals: Strong sector concentration in Healthcare (21 signals) suggests sector-specific rotation. 10 signals showing insider selling warrant caution.

Trading tips for this strategy:

• Entry timing: Enter on pullback after crossover or at crossover close price
• Position sizing: Start with 2-3% of portfolio per signal (swing trade size)
• Stop loss: Below recent swing low for buys, above recent swing high for sells
• Take profit: 5-10% target for swings, or trail stop at EMA10
• Time stop: Exit if crossover reverses within 1-2 weeks (failed signal)

Risk warning: EMA crossovers generate more signals but higher whipsaw risk in ranging markets. Use with trend filter (price vs SMA200)

Sharing Call-to-Action

✅ If this added value to your research, consider liking, sharing, or subscribing. It genuinely helps.

Independent, data-driven signals.
No hype. No promotions. Just experimental market research from EverHint.

This is not financial advice. Do your own due diligence.
See https://www.everhint.com/disclaimer/ and https://www.everhint.com/faqs/